Mutations in BRAF and NRAS were identified in 40.1 and 24.4% of casesBRAF was mutated in 87 cases (40.1%), while 53 patients (24.4%) showed NRAS mutationsThe highest portion of the aggressive NM subtype was observed in NRAS-mutant patients (52.0%)kinase inhibitorsimmune checkpoint blockade (ICB) with ipilimumab, nivolumab, or pembrolizumab. Here, BRAF is linked to nemaline myopathy.